ATE382366T1 - Modifizierte myelin proteinmoleküle - Google Patents

Modifizierte myelin proteinmoleküle

Info

Publication number
ATE382366T1
ATE382366T1 AT96913035T AT96913035T ATE382366T1 AT E382366 T1 ATE382366 T1 AT E382366T1 AT 96913035 T AT96913035 T AT 96913035T AT 96913035 T AT96913035 T AT 96913035T AT E382366 T1 ATE382366 T1 AT E382366T1
Authority
AT
Austria
Prior art keywords
polypeptides
plp
useful
modified
mbp
Prior art date
Application number
AT96913035T
Other languages
English (en)
Inventor
John Mueller
Michael Lenardo
Henry Mcfarland
Louis Matis
Eileen Mueller
Steven Nye
Clara Pelfrey
Stephen Squinto
James Wilkins
Original Assignee
Alexion Pharma Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/431,644 external-priority patent/US7041503B2/en
Application filed by Alexion Pharma Inc, Us Health filed Critical Alexion Pharma Inc
Application granted granted Critical
Publication of ATE382366T1 publication Critical patent/ATE382366T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT96913035T 1995-05-02 1996-04-22 Modifizierte myelin proteinmoleküle ATE382366T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43164895A 1995-05-02 1995-05-02
US08/431,644 US7041503B2 (en) 1995-05-02 1995-05-02 Modified myelin basic protein molecules
US48211495A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ATE382366T1 true ATE382366T1 (de) 2008-01-15

Family

ID=27411744

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96913035T ATE382366T1 (de) 1995-05-02 1996-04-22 Modifizierte myelin proteinmoleküle

Country Status (8)

Country Link
EP (1) EP0830139B1 (de)
JP (1) JPH11511650A (de)
KR (1) KR100682350B1 (de)
AT (1) ATE382366T1 (de)
AU (1) AU5565896A (de)
CA (1) CA2218858A1 (de)
DE (1) DE69637391T2 (de)
WO (1) WO1996034622A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US7041503B2 (en) 1995-05-02 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Modified myelin basic protein molecules
US6737057B1 (en) 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
JP2001512976A (ja) * 1997-02-25 2001-08-28 ジェンザイム・トランスジェニックス・コーポレーション トランスジェニックにより産生された非分泌性タンパク質
EP1522591A3 (de) * 1997-02-25 2005-08-17 GTC Biotherapeutics, Inc. Transgen produzierte nicht-sekretierte Proteine
IL132611A0 (en) 1999-10-27 2001-03-19 Yeda Res & Dev Synthetic genes and polypeptides and pharmaceutical compositions comprising them
CN1301752A (zh) * 1999-12-29 2001-07-04 复旦大学 一种新的多肽——plp蛋白10和编码这种多肽的多核苷酸
CN1301756A (zh) * 1999-12-29 2001-07-04 复旦大学 一种新的多肽——髓磷脂p0蛋白14和编码这种多肽的多核苷酸
IL146016A0 (en) 2001-10-17 2002-07-25 Yeda Res & Dev Synthetic peptides and dna sequences and compositions comprising them for treatment of multiple sclerosis
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
HUE027196T2 (hu) * 2002-09-06 2016-10-28 Genentech Inc Eljárás fehérjeextrakcióra
WO2004060910A2 (en) * 2002-12-16 2004-07-22 Wayne State University Bioactive peptides and unique ires elements from myelin proteolipid protein plp/dm20
WO2005080985A2 (en) * 2004-02-18 2005-09-01 Enteron Limited Partnership Methods and compositions for detecting and treating autoimmune diseases
KR100791996B1 (ko) * 2006-08-02 2008-01-04 고려대학교 산학협력단 미엘린 염기성 폴리펩타이드를 분비하는 형질전환 미생물을함유하는 자가면역질환 치료용 조성물
CA2979038A1 (en) * 2015-03-09 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006727A2 (en) * 1993-09-03 1995-03-09 Immulogic Pharmaceutical Corporation Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease

Also Published As

Publication number Publication date
DE69637391T2 (de) 2008-08-14
CA2218858A1 (en) 1996-11-07
DE69637391D1 (de) 2008-02-14
MX9708418A (es) 1998-10-31
AU5565896A (en) 1996-11-21
EP0830139B1 (de) 2008-01-02
KR19990008329A (ko) 1999-01-25
EP0830139A1 (de) 1998-03-25
JPH11511650A (ja) 1999-10-12
WO1996034622A1 (en) 1996-11-07
EP0830139A4 (de) 2001-10-10
KR100682350B1 (ko) 2008-11-06

Similar Documents

Publication Publication Date Title
ATE382366T1 (de) Modifizierte myelin proteinmoleküle
NO982794D0 (no) Diagnostisering og behandling av AUR-1 og/eller AUR-2 relaterte lidelser
FR2751986B1 (fr) Gene implique dans le cadasil, methode de diagnostic et application therapeutique
DE69729473D1 (de) Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems
CY1105446T1 (el) Διαγνωση και θepαπεια διαταραχων που συνδεονται με aur1 και aur2
DK1295944T3 (da) GDP-dissociationsstimulerende protein, hjernespecifikt nukleosomsamlingsprotein, skeletmuskelspecifikt ubiquitinkonjugerende enzym, celleproliferationsprotein, phosphatidylinositolkinase, nelbeslægtede proteiner
DE60142693D1 (de) Arzneimittel für herzversagen
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
DE69432934D1 (de) Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein
BR9408025A (pt) Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
DE69510810D1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
PT862622E (pt) Metodo de rastreio para compostos que interagem com proteina cinase rac
BR0009805A (pt) Mutações de enos úteis para terapia genética e rastreamento terapêutico
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
DE69329656D1 (de) Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase-peptidantigenen exprimierenden zellen
ATE449847T1 (de) Hepatitis c rezeptorprotein cd81
DK1373502T3 (da) Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf
NO963487L (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
ATE317021T1 (de) Antisense modulierung von lfa-3
Durussel et al. Cation-and peptide-binding properties of human calmodulin-like skin protein
DE69734890D1 (de) Rdgb-proteine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties